249 related articles for article (PubMed ID: 16505102)
1. A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.
Marchand C; Antony S; Kohn KW; Cushman M; Ioanoviciu A; Staker BL; Burgin AB; Stewart L; Pommier Y
Mol Cancer Ther; 2006 Feb; 5(2):287-95. PubMed ID: 16505102
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitors.
Song Y; Shao Z; Dexheimer TS; Scher ES; Pommier Y; Cushman M
J Med Chem; 2010 Mar; 53(5):1979-89. PubMed ID: 20155916
[TBL] [Abstract][Full Text] [Related]
3. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.
Staker BL; Feese MD; Cushman M; Pommier Y; Zembower D; Stewart L; Burgin AB
J Med Chem; 2005 Apr; 48(7):2336-45. PubMed ID: 15801827
[TBL] [Abstract][Full Text] [Related]
4. The binding orientation of a norindenoisoquinoline in the topoisomerase I-DNA cleavage complex is primarily governed by pi-pi stacking interactions.
Song Y; Cushman M
J Phys Chem B; 2008 Aug; 112(31):9484-9. PubMed ID: 18636761
[TBL] [Abstract][Full Text] [Related]
5. Indenoisoquinoline Topoisomerase Inhibitors Strongly Bind and Stabilize the
Wang KB; Elsayed MSA; Wu G; Deng N; Cushman M; Yang D
J Am Chem Soc; 2019 Jul; 141(28):11059-11070. PubMed ID: 31283877
[No Abstract] [Full Text] [Related]
6. Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings.
Nagarajan M; Morrell A; Fort BC; Meckley MR; Antony S; Kohlhagen G; Pommier Y; Cushman M
J Med Chem; 2004 Nov; 47(23):5651-61. PubMed ID: 15509164
[TBL] [Abstract][Full Text] [Related]
7. The mechanism of topoisomerase I poisoning by a camptothecin analog.
Staker BL; Hjerrild K; Feese MD; Behnke CA; Burgin AB; Stewart L
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15387-92. PubMed ID: 12426403
[TBL] [Abstract][Full Text] [Related]
8. A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor.
Morrell A; Antony S; Kohlhagen G; Pommier Y; Cushman M
J Med Chem; 2006 Dec; 49(26):7740-53. PubMed ID: 17181156
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of bisindenoisoquinolines as topoisomerase I inhibitors.
Nagarajan M; Morrell A; Antony S; Kohlhagen G; Agama K; Pommier Y; Ragazzon PA; Garbett NC; Chaires JB; Hollingshead M; Cushman M
J Med Chem; 2006 Aug; 49(17):5129-40. PubMed ID: 16913702
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors.
Cushman M; Jayaraman M; Vroman JA; Fukunaga AK; Fox BM; Kohlhagen G; Strumberg D; Pommier Y
J Med Chem; 2000 Oct; 43(20):3688-98. PubMed ID: 11020283
[TBL] [Abstract][Full Text] [Related]
11. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints.
Pommier Y
Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):429-34. PubMed ID: 15379698
[TBL] [Abstract][Full Text] [Related]
12. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
[TBL] [Abstract][Full Text] [Related]
13. Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors.
Morrell A; Placzek M; Parmley S; Grella B; Antony S; Pommier Y; Cushman M
J Med Chem; 2007 Sep; 50(18):4388-404. PubMed ID: 17676830
[TBL] [Abstract][Full Text] [Related]
14. Nitrated indenoisoquinolines as topoisomerase I inhibitors: a systematic study and optimization.
Morrell A; Placzek M; Parmley S; Antony S; Dexheimer TS; Pommier Y; Cushman M
J Med Chem; 2007 Sep; 50(18):4419-30. PubMed ID: 17696418
[TBL] [Abstract][Full Text] [Related]
15. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies.
Teicher BA
Biochem Pharmacol; 2008 Mar; 75(6):1262-71. PubMed ID: 18061144
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Flp recombinase by the topoisomerase I-targeting drugs, camptothecin and NSC-314622.
Frøhlich RF; Hansen SG; Lisby M; Grainge I; Westergaard O; Jayaram M; Knudsen BR
J Biol Chem; 2001 Mar; 276(10):6993-7. PubMed ID: 11152668
[TBL] [Abstract][Full Text] [Related]
17. Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity.
Antony S; Agama KK; Miao ZH; Hollingshead M; Holbeck SL; Wright MH; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
Mol Pharmacol; 2006 Sep; 70(3):1109-20. PubMed ID: 16798938
[TBL] [Abstract][Full Text] [Related]
18. On the binding of indeno[1,2-c]isoquinolines in the DNA-topoisomerase I cleavage complex.
Xiao X; Antony S; Pommier Y; Cushman M
J Med Chem; 2005 May; 48(9):3231-8. PubMed ID: 15857129
[TBL] [Abstract][Full Text] [Related]
19. Camptothecins as probes of the microenvironments of topoisomerase I--DNA complexes.
Hecht SM
Ann N Y Acad Sci; 2000; 922():76-91. PubMed ID: 11193927
[TBL] [Abstract][Full Text] [Related]
20. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition.
Pommier Y
Chem Rev; 2009 Jul; 109(7):2894-902. PubMed ID: 19476377
[No Abstract] [Full Text] [Related]
[Next] [New Search]
